Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2025 | $7.00 | Buy | Rodman & Renshaw |
| 6/26/2024 | $10.00 | Buy | ROTH MKM |
| 4/22/2024 | $9.00 | Buy | H.C. Wainwright |
| 12/17/2021 | $8.00 | Overweight | Cantor Fitzgerald |
| 12/3/2021 | $8.00 | Buy | Canaccord Genuity |
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application.Data from Cardiol's Phase II MAvERIC-Pilot study presented at the American Heart Association Scientific Sessions 2024 showed that pericarditis patients treated with CardiolRx™ experienced marked and rapid reductions in pericarditis pain and inflammation, and a substantial reduction in the number of pericarditis recurrences per year.Recurrent pericarditis
Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trialCompleted patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patientswith acute myocarditis, with topline data expected in Q2 2025CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditisCash and cash equivalents of $30.6 million as of December 31, 2024,to fund operations into Q3 2026Toronto, Ontario--(Newsfile Corp. - April 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) (
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025, at 11:10 a.m. EST.A replay of the live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/). About Cardiol Therapeutics Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL)
SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)
SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)
SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)
Rodman & Renshaw initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $7.00
ROTH MKM initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $10.00
H.C. Wainwright initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $9.00
6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the "Meeting") held virtually via live audio webcast, on June 26, 2024. Shareholders voted in favour of all management resolutions proposed in the Company's management information circular dated May 13, 2024.Resolutions proposed and approved at the Meeting were:The election of the following directors for the
Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28, 2023. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular. Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year: David Elsley, Peter Pekos, Dr. Gui
Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis - a debilitating heart disease associated with chest pain, shortness of breath and fatigue, resulting in markedly reduced quality of life, emergency department visits, and hospitalizationsInitiated patient enrollment in the ARCHER Trial - a Phase II multi-national, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of CardiolRx™ in patients with acute myocarditis, an important cause of acute and sudden heart failure in young adults and a leading cause of sudden cardiac death in people less